Tvardi Therapeutics (TVRD) Assets Average (2014 - 2026)
Tvardi Therapeutics (TVRD) posted Assets Average of $28.9 million for Q1 2026, down 18.57% sequentially from $35.5 million in Q4 2025, and down 21.92% YoY from $37.1 million in Q1 2025.
Tvardi Therapeutics (TVRD) Assets Average (2014 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Assets Average for 13 years, with the latest figure at $28.9 million in Q1 2026.
- Quarterly Assets Average fell 21.92% year-over-year to $28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.9 million (down 21.92% YoY) and the FY2025 annual result came in at $33.6 million, down 58.23% from the prior year.
- Assets Average slipped to $28.9 million in Q1 2026 per TVRD's latest filing, from $35.5 million in the prior quarter.
- Over five years, Assets Average peaked at $235.5 million in Q1 2022 and troughed at $28.9 million in Q1 2026.
- A 5-year average of $112.6 million and a median of $108.0 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average fell 1.45% in 2022, then plunged 65.66% in 2025.
- Over 5 years, Assets Average stood at $197.9 million in 2022, then sank by 39.06% to $120.6 million in 2023, then sank by 64.12% to $43.3 million in 2024, then retreated by 17.84% to $35.5 million in 2025, then slipped by 18.57% to $28.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $28.9 million, $35.5 million, and $41.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 21.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.95 Mn |
| Dec 31, 2025 | 35.55 Mn |
| Sep 30, 2025 | 41.39 Mn |
| Jun 30, 2025 | 41.35 Mn |
| Mar 31, 2025 | 37.07 Mn |
| Dec 31, 2024 | 43.26 Mn |
| Sep 30, 2024 | 61.91 Mn |
| Jun 30, 2024 | 81.30 Mn |
| Mar 31, 2024 | 107.97 Mn |
| Dec 31, 2023 | 120.59 Mn |
| Sep 30, 2023 | 124.86 Mn |
| Jun 30, 2023 | 143.83 Mn |
| Mar 31, 2023 | 167.76 Mn |
| Dec 31, 2022 | 197.87 Mn |
| Sep 30, 2022 | 220.04 Mn |
| Jun 30, 2022 | 225.22 Mn |
| Mar 31, 2022 | 235.46 Mn |
| Dec 31, 2021 | 236.07 Mn |
| Sep 30, 2021 | 223.27 Mn |
| Jun 30, 2021 | 235.84 Mn |